With shorter half-lives and more predictable effects, direct oral anticoagulants (DOACs) could help simplify perioperative treatment decisions for patients with non-valvular atrial fibrillation (NVAF), suggests a meta-analysis published May 24 in Circulation.
Countries in the Mediterranean region—thought to have one of the healthiest diets in the world—now have the highest rates of childhood obesity in Europe, according to data presented last week.
Severe and active atopic eczema in adulthood is associated with an increased risk for developing cardiovascular disease (CVD), including stroke, heart failure, myocardial infarction (MI) and atrial fibrillation (AFib), according to a new study published May 23 in The BMJ.
The FDA has cleared a robotic system that can noninvasively assess abnormal blood flow to the brain, helping diagnose and triage patients with ischemic strokes and other neurologic disorders.
A higher testosterone-to-estrogen ratio could be a harbinger of future cardiovascular disease (CVD) among post-menopausal women, according to a study published May 28 in the Journal of the American College of Cardiology.
Work-life balance is the chief determinant that leads internal medicine (IM) trainees to select cardiology as a career, according to a study published May 30 in JAMA Cardiology.
Several models have been developed to predict mortality among heart failure patients, but clinicians remain reluctant to use them in everyday practice. In fact, fewer than 1 percent of patients received a prognostic estimate from their physicians in a European registry analysis published in JACC: Heart Failure.
Human growth hormone showed the potential to improve the memory and cognitive function of mice post-stroke, raising the possibility of a similar treatment for humans.
Hypertensive patients collect $1,920 more in annual healthcare expenditures compared to healthy individuals, according to a study published in the Journal of the American Heart Association on May 30.
WAYNE, N.J., May 25, 2018 — Getinge, a leading global provider of innovative medical technology, today announced results from the Survival Improvement in Extensive Myocardial Infarction with PERsistent Ischemia Following IABP Implantation (SEMPER FI) pilot study.
